{
    "symbol": "SIBN",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 22:11:14",
    "content": " In the U.S., our revenue grew 18% in the quarter compared to a prior year period to a record $23.8 million, which was driven primarily by the robust demand for our procedures. While preliminary, the current proposal would increase calendar year 2023 facility reimbursement for minimally invasive SI joint fusion procedures performed in ASCs and hospital outpatient settings by approximately 28% and 35%, respectively. Our second quarter 2022 total revenue was $25.6 million, representing growth of approximately 15% compared to the prior year period."
}